Background and Aims: Long-term lamivudine therapy is required for patients with chronic hepatitis B, because hepatitis reappears frequently after it has withdrawn. However, hepatitis B virus (HBV) ...
Entecavir, a drug approved by the Food and Drug Administration for the treatment of chronic hepatitis B virus (HBV) infection, is not believed to inhibit replication of human immunodeficiency virus ...
The Appraisal Committee considered evidence submitted by the manufacturer of entecavir and a review of this submission by the Evidence Review Group (ERG). The manufacturer approached the initial ...
With Gift Aid, your generous donation of £10 would be worth £12.50 at no extra cost to you. Yes, I want to Gift Aid any donations made to NAM now, in the future and in the past four years I am a UK ...
With Gift Aid, your generous donation of £10 would be worth £12.50 at no extra cost to you. Yes, I want to Gift Aid any donations made to NAM now, in the future and in the past four years I am a UK ...
August 25, 2010 — Long-term antiviral therapy for 3 years or more with entecavir reverses fibrosis and cirrhosis in patients with chronic hepatitis B virus (HBV) infection, according to a new study ...
A two-year trial of entecavir followed by lamivudine in patients with chronic hepatitis B virus (HBV) infection resulted in a virologic rebound rate of 24 percent and 12 percent drug-resistance rate.
Long-term mortality outcomes were similar in patients with CHB receiving treatment with entecavir or tenofovir. Patients with chronic hepatitis B (CHB) treated with entecavir vs tenofovir disoproxil ...
PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE:BMY) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) of ...
SAN FRANCISCO, CA—Third-year results of a “real-world” cohort study found the antivirals entecavir and tenofovir provided comparable efficacy for treatment-naïve patients with chronic hepatitis B and ...
PUNE, India, July 07, 2021 (GLOBE NEWSWIRE) -- The Global Entecavir Market Share, Trends, Analysis and Forecasts, 2021-2031 provides insights on key developments, business strategies, research & ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results